Breaking News

Teva Names Global BD EVP

April 29, 2013

Sekhri brings more than 25 years of experience

Paul J. Sekhri has been appointed group executive vice president, Global Business Development and chief strategy officer of Teva Pharmaceutical Industries Ltd., effective June 15, 2013. In his new role, Mr. Sekhri will oversee Teva’s strategy and business development group, reporting directly to Dr. Jeremy Levin, Teva’s president and chief executive officer.
 
Mr. Sekhri has more than 25 years of operational experience in the industry, including business development, business strategy, general management, drug development, and commercial strategy. Mr. Sekhri most recently served as operating partner and head, Biotech Ops Group at TPG Biotech, the life science arm of the global private investment firm TPG, where he was responsible for a portfolio of more than 50 life science firms. Previously, Mr. Sekhri founded and was president and chief executive officer of Cerimon Pharmaceuticals, focused on autoimmune diseases and pain management. Prior to that, he was president and chief business officer of Ariad Pharmaceuticals. He also held senior positions at Novartis Pharma AG, and managerial roles at Millipore Corp. and PerSeptive Biosystems.
 
“Paul brings outstanding business development and operating experience in the life sciences industry, including with biotechnology, pharmaceutical and generic companies,” said Dr. Levin. “While we remain disciplined in our use of resources, we are committed to secure significant opportunities in key capabilities, generics and specialty medicines through our Constellation strategy. An appropriately targeted and aggressive business development strategy is central to Teva’s approach to sustainable growth.”
blog comments powered by Disqus
  • FDA & Drug Development

    FDA & Drug Development

    Rachelle Du2019Souza, Regulatory Heights Inc.||September 8, 2016
    You must perform the necessary due diligence to stay on top of regulatory developments

  • The Role of Alliances in Modern Drug Development

    The Role of Alliances in Modern Drug Development

    Dr. Claire Madden-Smith, Senior Vice President, Juniper Pharma Services||September 8, 2016
    Combining expertise to get drug candidates through development

  • Successful Method Transfer of Solid Oral Dosage

    Successful Method Transfer of Solid Oral Dosage

    John Frankonis, Ropack Pharma Solutions||June 2, 2016
    The three steps outlined will help guide the process of completing a successful analytical method transfer